Valneva SE is a specialty vaccine company headquartered in France whose American Depositary Shares trade on Nasdaq under the ticker VALN. Because it is a stock with several current, attributable analyst targets, the central target is built directly from those figures rather than a headline consensus.
Five individually verified targets were reviewed, ranging from roughly $4.90 to $18.00. Averaging them produces about $12.20, which rounds to a central target of $12. The range is exceptionally wide: Goldman Sachs' Rajan Sharma downgraded the stock to Sell with a $4.90 target in April 2026, while H.C. Wainwright's Brandon Folkes reiterated a Buy with an $18 target in September 2026. Between those extremes sit Jefferies at $15, TD Cowen at $12, and Guggenheim at $11.
The dispersion reflects genuinely different views of the same story. Bulls weight the Pfizer-partnered Lyme vaccine (VLA15) toward commercial potential, while cautious analysts focus on the August 2025 suspension of the U.S. chikungunya vaccine (IXCHIQ) license and the company's persistent net losses. Third-party aggregators report a similar mean of roughly $12.25–$12.28, consistent with the calculation used here.
As of early November 2026, VALN traded near $5.66, toward the lower end of its 52-week range of $4.75 to $12.18. The company has a market capitalization around $540 million and reported trailing twelve-month revenue of roughly $163 million against a net loss near $180 million.
Closing the gap to $12 would require upside of about 112%, which is a very large move. Such a move would likely depend less on near-term financial results and more on successful execution of the Lyme vaccine program — including Phase 3 data maturation and regulatory submissions — as well as stabilization or recovery in the chikungunya franchise. At current prices, the market is assigning limited value to pipeline optionality, so any positive regulatory or partnership milestone could drive a meaningful re-rating.
The stock sits about $0.90 above its 52-week low of $4.75, a level that acts as a key support zone. Recent trading has consolidated around $5.30–$5.66, with near-term resistance near the $6 area. More durable resistance lies at the psychological $10 level and then the 52-week high of $12.18 — almost exactly the central target. In practical terms, reaching $12 would mean reclaiming the stock's prior high and reversing a prolonged downtrend, a technically demanding feat without a decisive fundamental catalyst.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms rarely state a fixed date and horizons can differ. The most important near-term event is Valneva's next earnings release, scheduled for late November 2026, which may update 2026 guidance and commentary on the Lyme and chikungunya programs.
Investors should also watch for Lyme vaccine regulatory submissions by Pfizer, any chikungunya regulatory developments, partnership or financing announcements, and analyst target revisions, which have been frequent given the stock's volatility. Macroeconomic factors such as interest rates and risk appetite for pre-revenue biotech also matter for a small-cap vaccine developer.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. For those tracking a volatile name like VALN, automated signal scanning can complement fundamental research by flagging momentum changes as they develop.
The question of whether Valneva SE can reach $12 is really a question about whether its pipeline value will be recognized. The $12 central target, derived from an average of five analyst targets spanning $4.90 to $18.00, implies a very large gain of roughly 112% from the recent price near $5.66. Support rests on the Lyme vaccine program and stabilizing revenue, while the obstacles include the chikungunya setback, ongoing losses, thin liquidity, and heavy technical overhead near the prior 52-week high. The wide analyst spread underscores genuine uncertainty rather than a clear directional signal. Investors should focus on upcoming earnings, Lyme regulatory milestones, and analyst revisions, while keeping in mind that analyst targets are estimates, not guarantees.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VALN has been loosely correlated with IMTX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if VALN jumps, then IMTX could also see price increases.
| Ticker / NAME | Correlation To VALN | 1D Price Change % | ||
|---|---|---|---|---|
| VALN | 100% | +2.72% | ||
| IMTX - VALN | 33% Loosely correlated | +1.10% | ||
| BMRN - VALN | 32% Poorly correlated | +2.05% | ||
| ORMP - VALN | 29% Poorly correlated | +3.63% | ||
| BOLT - VALN | 28% Poorly correlated | -1.68% | ||
| SPRO - VALN | 27% Poorly correlated | +3.88% | ||
More | ||||